⌘K
Loading ticker…
As of 2026-08-24, Innoviva, Inc. Common Stock (INVA) has a 3-month relative strength percentile of 35 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 47. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.3%, relative volume 0.76×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
INVA is in a stage 3 topping pattern, week 3. Currently in a 124-day base; basing ADR 2.6% (broad 2.7%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: -3.4% / -3.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
INVA appears in 1 ETF as of Jun 2026: PSC at 0.07% weight, $2M notional.
Held by 118 ETFs · $518M across latest filings · largest weight 2.88% (PJP).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.07% | $2M | −0.02 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | INVA Jan avg: 0.99% median: 0.52% win: 75% σ: 4.93% n: 4 2022-04-12 → 2026-07-31 | INVA Feb avg: 0.17% median: -4.22% win: 25% σ: 9.78% n: 4 2022-04-12 → 2026-07-31 | INVA Mar avg: -1.10% median: 0.46% win: 50% σ: 3.87% n: 4 2022-04-12 → 2026-07-31 | INVA Apr avg: -1.15% median: -0.85% win: 40% σ: 5.97% n: 5 2022-04-12 → 2026-07-31 | INVA May avg: 1.26% median: 4.50% win: 60% σ: 10.36% n: 5 2022-04-12 → 2026-07-31 | INVA Jun avg: 0.84% median: 2.66% win: 60% σ: 4.84% n: 5 2022-04-12 → 2026-07-31 | INVA Jul avg: 0.25% median: -2.85% win: 40% σ: 10.26% n: 5 2022-04-12 → 2026-07-31 | INVA Aug avg: 0.29% median: -1.52% win: 50% σ: 9.40% n: 4 2022-04-12 → 2026-07-31 (current) | INVA Sep avg: -5.23% median: -5.52% win: 25% σ: 6.99% n: 4 2022-04-12 → 2026-07-31 | INVA Oct avg: 3.34% median: 0.51% win: 50% σ: 9.30% n: 4 2022-04-12 → 2026-07-31 | INVA Nov avg: 6.23% median: 4.35% win: 50% σ: 11.17% n: 4 2022-04-12 → 2026-07-31 | INVA Dec avg: 0.02% median: -3.55% win: 50% σ: 11.39% n: 4 2022-04-12 → 2026-07-31 |